Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer]

[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Abstract Text:

    xiao-dong zhangXiao-dong Zhang,lin shenLin Shen,yan liYan Li,jie liJie Li,bo-qin yangBo-qin Yang,mao-lin jinMao-lin Jin,

    OBJECTIVE: To evaluate the therapeutic effects of hydroxycamptothecin (H) combined with leucovorin (L), fluorouracil (F) and cisplatin (P) on advanced cancer of gastric cardia and colorectal cancer. METHODS: Sixty-five patients with advanced cancer of gastric cardia or colorectal cancer were treated by LFH or LFPH regimen. All patients completed four cycles of treatment, in 21 days per cycle. RESULTS: The overall response rate (RR) was 26.2% (17/65) with partial response (PR) in 17 patients, stable disease (SD) in 31 and progressive disease (PD) in 17. The clinical benefit response rate (CR + PR + SD) was 73.8% (48/65). The RR were 32.3% (10/31) for untreated patients and 20.6% (7/34) for retreated patients. The stable rate was 47.7% (31/65). The RR of patients with cancer of gastric cardia were 33.3% (5/15) for untreated treatment and 29.4% (5/17) for retreated ones. Median survival time (MST) was 10 months. Median time to progression (MTTP) was 8 months. Grade 3 - 4 toxicities were stomatitis (10.8%), nausea and vomiting (12.3%) and leukopenia (6.2%). Most patients (> 80%) developed Grade 1 - 2 alopecia. CONCLUSION: The regimen of HCPT combined with LV, 5-Fu and DDP appears to be an effective and tolerable therapeutic option for advanced cancer of gastric cardia and colorectal cancer, especially for the former and retreated patients, giving a satisfactory stable rate though not very high.

    [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Publishing Authors By Initials

    xd zhangXD Zhang,l shenL Shen,y liY Li,j liJ Li,bq yangBQ Yang,ml jinML Jin,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Zhonghua zhong liu za zhi [Chinese journal of onco

    VOLUME: 25

    Page Numbers: 289-91

    Journal Abbreviation: Zhonghua Zhong Liu Za Zhi

    ISSN: 0253-3766

    DAY: 3

    MONTH: May

    YEAR: 2003

    [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Information

    Number of References:

    LANGUAGE: chi

    NlmUniqueID: 7910681

    [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer]

    AFFILIATION: Department of Gastrointestinal Medicine, Beijing University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital. Beijing 100036, China.

    Country: China

    China Research PublicationChina Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Zhonghua Zhong Liu Za Zhi

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News